title: Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
abstract: Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.
authors.affiliation: Cardiology Unit, Centro di Riferimento Oncologico di Basilicata IRCCS, Via Padre Pio 1, 85028 Rionero in Vulture (PZ), Italy. pina.gallucci@tiscali.it
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Gallucci
authors.forename: Alfredo
authors.initials: A
authors.lastname: Tartarone
authors.forename: Carlo Gabriele
authors.initials: CG
authors.lastname: Tocchetti
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Bochicchio
authors.forename: Mariarosa
authors.initials: M
authors.lastname: Coccaro
authors.forename: Alba
authors.initials: A
authors.lastname: Capobianco
authors.forename: Nicola
authors.initials: N
authors.lastname: Maurea
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Improta
authors.forename: Angela
authors.initials: A
authors.lastname: Zupa
authors.forename: Michele
authors.initials: M
authors.lastname: Aieta
mesh_terms: D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000378:metabolism*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011225:Pre-Eclampsia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D011247:Pregnancy; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib